Código QR (código de barras bidimensional)

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell subsets; and increases stringency on B cell selec...

ver descrição completa

Na minha lista:
Principais autores: Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L. Clark, Salvatore De Vita, David H. Gardner, Robert B. Henderson, Michael Herdman, Karoline Lerang, Prafull Mistry, Raj Punwaney, Raphaele Seror, John Stone, Paul L.A. van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth, Paul Peter Tak
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical investigation 2022-12-01
coleção:JCI Insight
Assuntos:
Clinical trials
Immunology
Acesso em linha:https://doi.org/10.1172/jci.insight.163030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados